These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36550639)

  • 21. SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors.
    Leon J; Merrill AE; Rogers K; Kurt J; Dempewolf S; Ehlers A; Jackson JB; Knudson CM
    Transfus Apher Sci; 2022 Apr; 61(2):103326. PubMed ID: 34862140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Motivation, blood donor satisfaction and intention to return during the COVID-19 pandemic.
    Weidmann C; Derstroff M; Klüter H; Oesterer M; Müller-Steinhardt M
    Vox Sang; 2022 Apr; 117(4):488-494. PubMed ID: 34725833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics and Motivational Factors of Whole Blood and Convalescent Plasma Donors during the SARS-CoV-2 Pandemic in Israel.
    Shinar E; Jaffe E; Orr Z; Zalcman BG; Offenbacher J; Quint M; Alpert EA; Weiss BZ; Berzon B
    Healthcare (Basel); 2024 Mar; 12(5):. PubMed ID: 38470700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Qualifying coronavirus disease 2019 convalescent plasma donors in Israel.
    Izak M; Gendelman V; Bransburg-Zabary S; Stoyanov E; Gat R; Cohen D; Chen J; Maor Y; Benov A; Lev B; Zimhony O; Shinar E
    Vox Sang; 2022 Feb; 117(2):185-192. PubMed ID: 34125976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promoting access to COVID-19 convalescent plasma in low- and middle-income countries.
    Bloch EM; Goel R; Montemayor C; Cohn C; Tobian AAR
    Transfus Apher Sci; 2021 Feb; 60(1):102957. PubMed ID: 32972861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda.
    Muttamba W; Lusiba J; Namakula LO; Byakika-Kibwika P; Ssali F; Ddungu H; Mugenyi L; Kiwanuka N; Sekibira R; Kityo C; Keyune D; Acana S; Musinguzi A; Masasi A; Byamugisha J; Mpanju D; Musoki WJ; Tukamuhebwa HA; Nakwagala F; Bagaya BS; Kayongo A; Kimuli I; Nantanda R; Katagira W; Buregyeya E; Byanyima R; Byarugaba B; Siddharthan T; Mwebesa H; Charles O; Joloba ML; Bazeyo W; Kirenga B
    PLoS One; 2021; 16(6):e0252306. PubMed ID: 34138909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood donor return behavior in South Africa and the United States before and during the COVID-19 pandemic.
    Jagirdar H; Nwobi NH; Swanevelder R; Cockeran R; Bruhn R; Kaidarova Z; Bravo MD; van den Berg K; Custer BS; Vassallo R; Ding Y; Panagiotoglou D; Russell WA
    Transfusion; 2024 Aug; 64(8):1492-1502. PubMed ID: 38940011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Confronting the challenge of gender nonconforming donors: A blood center's three-year experience.
    Reynolds V; Van Buren NL; Gorlin JB
    Transfusion; 2023 Jul; 63(7):1284-1289. PubMed ID: 37265374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes.
    Yokoyama APH; Wendel S; Bonet-Bub C; Fachini RM; Dametto APF; Blumm F; Dutra VF; Candelaria GTP; Sakashita AM; Machado RRG; Fontão-Wendel R; Hamerschlak N; Achkar R; Assunção MSC; Scuracchio P; Nudelman V; Pastore L; Pinho JRR; Ben MD; Filho RK; Marra AR; Amano MT; Kallás EG; Helito AS; de Carvalho CRR; Araujo DB; Durigon EL; Camargo AA; Rizzo LV; Reis LFL; Kutner JM
    Transfusion; 2021 Aug; 61(8):2295-2306. PubMed ID: 34173248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.
    Bloch EM; Goel R; Wendel S; Burnouf T; Al-Riyami AZ; Ang AL; DeAngelis V; Dumont LJ; Land K; Lee CK; Oreh A; Patidar G; Spitalnik SL; Vermeulen M; Hindawi S; Van den Berg K; Tiberghien P; Vrielink H; Young P; Devine D; So-Osman C
    Vox Sang; 2021 Jan; 116(1):18-35. PubMed ID: 32533868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Provision of COVID-19 Convalescent Plasma in a Resource-Constrained State.
    Ipe TS; Le T; Quinn B; Kellar S; Clark M; Carlisle S; Rassmann A; Hennigan S; Ridenour T; Roberts A; Avery D; Ryan S; Pearson S; Kothari A; Patil N
    Transfusion; 2020 Dec; 60(12):2828-2833. PubMed ID: 32989778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Motivators of and barriers to becoming a COVID-19 convalescent plasma donor: A survey study.
    Masser BM; Ferguson E; Thorpe R; Lawrence C; Davison TE; Hoad V; Gosbell IB
    Transfus Med; 2021 Jun; 31(3):176-185. PubMed ID: 33368777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study.
    Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR
    Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Demographic and Clinical Factors Associated with Reactivity of Anti-SARS-CoV-2 Antibodies in Serbian Convalescent Plasma Donors.
    Grujić J; Bujandrić N; Budakov-Obradović Z; Dolinaj V; Bogdan D; Savić N; Cabezas-Cruz A; Mijatović D; Simin V; Anđelić N; Banović P
    Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor tolerability of convalescent plasma donation.
    He R; Lin H; Xie S; Lv Q; Kong Y; Li L; Xu H; Wang J; Li W; Fang P; Wu Y; Liu Z
    J Clin Apher; 2021 Jun; 36(3):429-436. PubMed ID: 33587767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A critical contribution in a time of crisis: Examining motivations and deterrents to COVID-19 convalescent plasma donation and future donation intentions among prospective Canadian donors.
    Holloway K; Campbell C; Ali R; Huyer LD; Hart D; Haw J; Brennenstuhl S; Grundy Q
    Transfus Med; 2022 Oct; 32(5):351-365. PubMed ID: 35578828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors.
    Annen K; Morrison TE; DomBourian MG; McCarthy MK; Huey L; Merkel PA; Andersen G; Schwartz E; Knight V
    Transfusion; 2021 Apr; 61(4):1148-1159. PubMed ID: 33452828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.
    Dodd RY; Spencer BR; Xu M; Foster GA; Saá P; Brodsky JP; Stramer SL
    Transfus Med Rev; 2021 Jul; 35(3):1-7. PubMed ID: 34373145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma.
    Yılmaz S; Ertuğrul Örüç N; Özcebe Oİ; Azap A; Çetin AT; Yenicesu İ; Öztürk A; Gündüz M; Tekin A
    Transfus Apher Sci; 2020 Oct; 59(5):102846. PubMed ID: 32593519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres.
    Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H
    Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.